In conclusion, this study highlights the importance of the miR-1193/YY1AP1/YY1/FEN1 axis as a promising therapeutic target for DNA-PKcs-deficient GBM tumors, with synthetic lethality as the mechanism of action. The gene discussed is YY1AP1; the disease is glioblastoma.